MAPPING OF MUTATIONS CONTRIBUTING TO THE TEMPERATURE SENSITIVITY OF THE SABIN-1 VACCINE STRAIN OF POLIOVIRUS
MAPPING OF MUTATIONS CONTRIBUTING TO THE TEMPERATURE SENSITIVITY OF THE SABIN-1 VACCINE STRAIN OF POLIOVIRUS
复制标题
DOI:
10.1128/jvi.69.9.5278-5286.1995
复制
发表时间:
1995-09-01
影响因子:
5.4
通讯作者:
DELPEYROUX, F
中科院分区:
文献类型:
--
作者:
GEORGESCU, MM;TARDYPANIT, M;DELPEYROUX, F
The temperature-sensitive and attenuated phenotypes of the Sabin type 1 vaccine strain of poliovirus result from numerous point mutations which occurred in the virulent Mahoney virus parent. One of these mutations is located in a 3D polymerase (3D(Pol)) codon (U-6203-->C, Tyr 73-->His) and is involved in attenuation in common mice (M. Tardy-Panit, B. Blondel, A. Martin, F. Tekaia, F. Horaud, and F. Delpeyroux, J. Virol. 67:4630-4638, 1993). This mutation also appears to contribute to temperature sensitivity in association with at least 1 other of the 10 mutations of the 3'-terminal part of the genome including the 3D(Pol) coding and 3' noncoding regions. To map the other mutation(s), we constructed poliovirus mutants by mutagenesis and recombination of Mahoney and Sabin 1 cDNAs. Characterization of these poliovirus mutants showed that a second mutation in a 3D(Pol) codon (C-7071-->U, Thr-362-->Ile) contributes to temperature sensitivity. A mutation in the 3' noncoding region of the genome (A-7441-->G), alone or linked to another mutation (U-7410-->C), also appeared to be involved in this phenotype. The temperature-sensitive effect associated with the 3'-terminal part of the Sabin 1 genome results from the cumulative and/or synergistic effects of at least three genetic determinants, i.e., the His-73 and Ile-362 codons of 3D(Pol) and nucleotide G-7441. Sequence analysis of strains isolated from patients with vaccine-associated paralytic poliomyelitis showed that these genetic determinants are selected against in vivo, although the Ile-362 codon appeared to be more stable than either the His-73 codon or G-7441. These genetic determinants may contribute to the safety of Sabin 1 in vaccinees.